Advertisement
Loading...

Genmab A/S

GMABā€¢NASDAQ
Healthcare
Biotechnology
$26.60
$0.05(0.19%)
U.S. Market is Open ā€¢ 15:42

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/Sā€™s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap16.5B
P/E Ratio6.33
EPS (TTM)$1.31
ROE0.21%
Fundamental Analysis

AI Price Forecasts

1 Month$29.18
3 Months$29.63
1 Year Target$34.68

GMAB Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Genmab A/S (GMAB) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.37, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.68.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 6.33 and a market capitalization of 16.5B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
1.32%
5-Day Change
5.24%
1-Month Change
-7.43%
3-Month Change
-10.42%
6-Month Change
-11.10%
Year-to-Date (YTD) Change
-12.66%
1-Year Change
40.99%
3-Year Change
-36.17%
5-Year Change
-27.45%
All-Time (Max) Change
613.53%

Contact Information

https://www.genmab.com
45 70 20 27 28
Kalvebod Brygge 43, Copenhagen, NaN, 1560

Company Facts

2,638 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions